Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.
PTC fails phase 3, and looks to a regulatory filing
Vatiquinone’s pivotal failure in Friedreich’s ataxia prompts a data dredge to come up with a regulatory package. And why not?
Here come the PD-1 agonists
Lilly shows that peresolimab is a goer, and others are not far behind; but what about the cancer risk?
Spotlight – Few signs of gout pipeline flaring up
Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.
